Boston, MA 02/20/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) could soon be without the services of its billionaire chairman Philip Frost if reports appearing on the media are true. It is reported that the entrepreneur might leave the Israel-based TEVA before his current terms expires next year. However, some other reports say that Mr. Frost has not set the actual date for his exit at TEVA. Perhaps investors need to know that the 77-year old businessman also holds two chairman positions in Ladenburg Thalmann Financial Services (NYSE:LTS) and Opko Health (NYSE:OPK). Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) was last seen with $1.75 gain per share to settle at $48.20.
Oi SA (ADR) (NYSE:OIBR) stock was last seen with more than 1.9 percent gain to $1.60 per share, after the company announced an ambitious plan to raise roughly $5.9 billion in shares offering. This stock offering plan was revealed in regulatory filing Thursday. The company needs money to tool up its operations and more so for the proposed merger with Portugal Telecom. OIBR and Portugal Telecom announced plans to join forces in October last year and they hope that the move will result into a new company boasting more than 100 million subscribers. Also, the resulting company is hoped would be able to generate excess of $19 billion in annual revenue. More importantly, the two telecoms companies teaming up in a merger will enable them to compete effectively against bigger rivals America Movil and Telefonica S.A. (ADR) (NYSE:TEF).
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shareholders seem to be excited by reports that one of the company’s biggest investors is vying to get two board seats. The investor in question is Sarissa Capital Management which is low the second largest shareholder in ARIA with roughly 6.2 percent stake. The investment vehicle is interested in two board seats at time when two directors are expected to stand for reelection. The board of ARIA has eight members. After investor booked profits over the past days, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) are back on the green zone, gaining more than 1.51 percent in the previous session to finish at $8.73.
